Adial Pharmaceuticals, Inc.
ADILHealthcareNASDAQBiotechnology · Last scanned Sep 5, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Adial Pharmaceuticals, Inc. focuses on Biotechnology services and products. Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Valued at $20.9M, ADIL is a micro-cap name in its sector. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder.
Market Cap
$20.9M
Beta
1.39
P/E (TTM)
—
P/E (Fwd)
-0.96
EPS (TTM)
$-18.63
EPS (Fwd)
$-7.45
ROE
-2011.6%
ROA
-40.0%
Cash
$28.7M
Total Debt
$0
Free CF
-$3.9M
52W Change
-23.9%
Annual Financials
Cash vs Debt
Where ADIL stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ADIL finished 129.82% above its 150-day moving average ($2.75) and 69.44% above its 200-day moving average ($3.73). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ADIL overbought or oversold?
At the September 3, 2026 close, ADIL's RSI(14) was 69.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Adial Pharmaceuticals, Inc. reports $28.7M in cash and $0 in total debt. Free cash flow is running at -$3.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -2011.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing ADIL's risk profile alongside its fundamentals and technical indicators provides a more complete picture.